Intravenous 5-fluorouracil in patients with advanced squamous cell carcinoma: A retrospective study
Annals of Allergy, Rhinology, & Laryngology Jun 29, 2018
Buxó E, et al. - Authors gauged the safety and effectiveness of carboplatin plus tegafur (an oral fluoropyrimidine) and cetuximab, with the aim of improving fluoropyrimidine-related tolerance without decreasing its efficacy. Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) were included in the study. Findings suggested safety and good tolerability of carboplatin plus oral tegafur and cetuximab first-line therapy for recurrent or metastatic HNSCC. Skin reactions, hypomagnesemia, asthenia, and anemia were included in grade 1-2 adverse events.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries